Home › Linfoma di Burkitt › Georgia
Studi clinici su Linfoma di Burkitt nello stato di Georgia
12 studi su Linfoma di Burkitt cercano partecipanti presso sedi nello stato di Georgia.
Città nello stato di Georgia
Testo ufficiale dello studio (inglese)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
- Augusta University Medical Center, Augusta
- Atrium Health Navicent, Macon
- e altri 1
In reclutamentoFase 2
366 Days – 46 Years · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Augusta University Medical Center, Augusta
In reclutamentoFase 3
Età da 18 a 39 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT03150693Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Healthcare of Atlanta - Arthur M. Blank Hospital, Atlanta
In reclutamentoStudio osservazionale
Età da 0 a 38 · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06131801Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
In reclutamentoFase 2
365 Days · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06317662Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Winship Cancer Institute Emory University, Atlanta
- Northside Hospital Cancer Institute, Atlanta
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT03666000A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
- Memorial Health University Medical Center, Savannah
In reclutamentoFase 2
Età da 1 a 30 · Tutti i sessi · Aggiornato il 1 set 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
- Augusta University Medical Center, Augusta
- Atrium Health Navicent, Macon
- e altri 1
In reclutamentoFase 3
365 Days – 25 Years · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Children's Healthcare of Atlanta at Egleston, Atlanta
In reclutamentoFase 2
Età da 7 a 25 · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT05082519AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, Atlanta
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT06137118Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- Winship Cancer Institute, Emory University, Atlanta
- Augusta Cancer Center, Augusta
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 nov 2025 · NCT04260022The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Children's Healthcare of Atlanta, Atlanta
In reclutamentoFase 2
Età da 1 a 25 · Tutti i sessi · Aggiornato il 4 mag 2025 · NCT03509961Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.